Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Pharmacology and Toxicology of the Interferons: An Overview

The Pharmacology and Toxicology of the Interferons: An Overview Gilbert J. Mannering and Laurel B. Deloria Department of Pharmacology , University of Minnesota School of Medicine, Minneapo­ lis, Minnesota 55455 INTRODUCTION2 Early virologists observed that a patient or an experimental animal, once recovered from a virus infection usually resisted reinfection from the same or similar virus. Vaccination was one of the early applications of this phenom­ enon, which was termed viral interference. As immunology evolved, in­ vestigators recognized that the infected body produces specific antiviral anti­ bodies which appear in the circulation and on mucous surfaces attacked by viruses (humoral immunity), or that sensitized cells (principally lymphocytes) appear which can attack both virus particles and cells infected by viruses (cell-mediated immunity). The requirement of specific antibodies for specific viruses limited the general clinical usefulness of humoral and cell-mediated immunity. As experience with cell cultures evolved, it became apparent with several experimental models that infection of cells with one virus protected against reinfection with an antigenically unrelated virus. The groundwork for the discovery of interferon was laid by Henle & Henle (6) in 1943 when they demonstrated interference between inactive and active influenza viruses in the developing chick embryo, but the mechanism of this type of interference was http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Pharmacology and Toxicology Annual Reviews

The Pharmacology and Toxicology of the Interferons: An Overview

Download PDF
61 pages

Loading next page...
 
/lp/annual-reviews/the-pharmacology-and-toxicology-of-the-interferons-an-overview-ZyiGwPj7Jm

References (136)

Publisher
Annual Reviews
Copyright
Copyright 1986 Annual Reviews. All rights reserved
Subject
Review Articles
ISSN
0362-1642
eISSN
1545-4304
DOI
10.1146/annurev.pa.26.040186.002323
pmid
2424363
Publisher site
See Article on Publisher Site

Abstract

Gilbert J. Mannering and Laurel B. Deloria Department of Pharmacology , University of Minnesota School of Medicine, Minneapo­ lis, Minnesota 55455 INTRODUCTION2 Early virologists observed that a patient or an experimental animal, once recovered from a virus infection usually resisted reinfection from the same or similar virus. Vaccination was one of the early applications of this phenom­ enon, which was termed viral interference. As immunology evolved, in­ vestigators recognized that the infected body produces specific antiviral anti­ bodies which appear in the circulation and on mucous surfaces attacked by viruses (humoral immunity), or that sensitized cells (principally lymphocytes) appear which can attack both virus particles and cells infected by viruses (cell-mediated immunity). The requirement of specific antibodies for specific viruses limited the general clinical usefulness of humoral and cell-mediated immunity. As experience with cell cultures evolved, it became apparent with several experimental models that infection of cells with one virus protected against reinfection with an antigenically unrelated virus. The groundwork for the discovery of interferon was laid by Henle & Henle (6) in 1943 when they demonstrated interference between inactive and active influenza viruses in the developing chick embryo, but the mechanism of this type of interference was

Journal

Annual Review of Pharmacology and Toxicology – Annual Reviews

Published: Apr 1, 1986

There are no references for this article.